Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS

Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology

Iza-bren delivers dual survival win in phase III trial for hard-to-treat breast cancer

Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival

IRLAB Therapeutics doses first patient in pivotal apathy trial

The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain

Chennai gets first structured geriatric continuity-of-care programme

Swayam is designed to support elderly patients and their families with seamless access to coordinated medical care

Novo Nordisk invests €432 million to expand Athlone facility for global Wegovy pill supply

The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202

Emcure partners with Roche to boost nephrology and transplant care in India

Emcure to distribute Roche's kidney transplant and anemia drugs in India

Eli Lilly and Incyte score key win for teens with severe alopecia areata in Europe

AA, a chronic immune disease, can cause extensive and unpredictable hair loss

Combination therapy cuts death Risk in advanced prostate cancer: PEACE-3 trial

PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer

Pfizer and Astellas report groundbreaking results in muscle-invasive bladder cancer trial

Novartis completes $12 billion acquisition of Avidity Biosciences

The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity